PROGRAM OVERVIEW
This educational Case Escalation Series is designed to improve your use of PI3K-pathway inhibitors for eligible patients with hormone-receptor‒positive, HER2-negative metastatic breast cancer through personalized and multidisciplinary treatment planning and adverse event management, as well as improved recognition of barriers to delivery of guideline-concordant care. This activity is comprised of three interactive, video-based modules that escalate in complexity. Each module includes a brief clinical primer, followed by case presentation and discussion. Throughout the modules, you will have the opportunity to share your approaches and perspectives, while watching the expert faculty provide evidence-based rationale for their own strategies. The activity also includes point-of-care resources such as personalized posters and video micromodules.
Sara Hurvitz, MD, FACP
Professor of Medicine
Smith Family Endowed Chair in Women’s Health
Head, Division of Hematology and Oncology
Senior Vice President, Clinical Research Division
Department of Medicine, UW Medicine
Fred Hutchinson Cancer Center
Seattle, Washington
Module 1: PI3K Pathway Inhibition for HR+, HER2- Metastatic Breast Cancer
Module 1 Overview
In module 1 of this case escalation series, Dr. Hurvitz presents the case of a 63-year-old woman diagnosed with metastatic recurrence of ER+, PR+, HER2-negative, breast cancer that develops 6 months after completion of 5 years of an adjuvant aromatase inhibitor. Her discussion explores biomarker-directed therapy for woman with advanced breast cancer, including molecular testing, treatment selection (eg, CDK4/6 inhibition with or without a PI3K pathway inhibitor), and the importance of baseline assessment of risk for treatment-related adverse events.
TARGET AUDIENCE
The proposed innovative educational initiative will be designed to meet the educational needs of community oncologists, members of the oncology care team (pharmacists, advanced practice providers, and nurses), and endocrinologists.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Select the most appropriate PI3K pathway inhibitor for patients with HR+/HER2- mBC based on the tumor mutational profile
- Summarize the mechanisms underlying hyperglycemia associated with PI3K pathway inhibitors, the characteristics of these AEs, and the impact on patients with HR+/HER2- metastatic breast cancer
- Develop strategies to monitor and manage hyperglycemia and other adverse events associated with PI3K pathway inhibitors effectively and promptly within an MDT
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of .25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of .25 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Disclosures |
| Sara Hurvitz, MD, FACP | Discloses that she receives royalties from McGraw Hill, Elsevier, Wolters Kluwer, and SAGE She receives consulting fees (paid to her institution) from Mersana, BMS, Beigene, Gilead, Daiichi Sankyo, Jazz, Roche, Luminate, Bridge, and Inclin/Atossa She receives research funding from AstraZeneca/Daiichi Sankyo, Novartis, Stemline/Menarini She has ownership interest in ROM Tech |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Kim Farina, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Andi Koral, MS, CMP-HC, Program Manager for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: October 02, 2025
EXPIRATION DATE: October 02, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited
Sara Hurvitz, MD, FACP
Professor of Medicine
Smith Family Endowed Chair in Women’s Health
Head, Division of Hematology and Oncology
Senior Vice President, Clinical Research Division
Department of Medicine, UW Medicine
Fred Hutchinson Cancer Center
Seattle, Washington
Module 2: Prediabetic Patient With PIK3CA-mutated, HR+, HER2- MBC
Module 2 Overview
In module 2 of this case escalation series, Dr. Hurvitz presents the case of an obese 69-year-old woman with baseline prediabetes who has PIK3CA-mutated, HR+, HER2-negative metastatic breast cancer that has progressed on an aromatase inhibitor + CDK4/6 inhibitor. The discussion explores the mechanisms underlying hyperglycemia associated with PI3K-pathway inhibition (PI3Ki), principles of risk-adapted blood glucose monitoring for patients who will receive a PI3Ki, as well as recommended dose modifications based on severity of hyperglycemia.
TARGET AUDIENCE
The proposed innovative educational initiative will be designed to meet the educational needs of community oncologists, members of the oncology care team (pharmacists, advanced practice providers, and nurses), and endocrinologists.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Select the most appropriate PI3K pathway inhibitor for patients with HR+/HER2- mBC based on the tumor mutational profile
- Summarize the mechanisms underlying hyperglycemia associated with PI3K pathway inhibitors, the characteristics of these AEs, and the impact on patients with HR+/HER2- metastatic breast cancer
- Develop strategies to monitor and manage hyperglycemia and other adverse events associated with PI3K pathway inhibitors effectively and promptly within an MDT
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of .25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of .25 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Disclosures |
| Sara Hurvitz, MD, FACP | Discloses that she receives royalties from McGraw Hill, Elsevier, Wolters Kluwer, and SAGE She receives consulting fees (paid to her institution) from Mersana, BMS, Beigene, Gilead, Daiichi Sankyo, Jazz, Roche, Luminate, Bridge, and Inclin/Atossa She receives research funding from AstraZeneca/Daiichi Sankyo, Novartis, Stemline/Menarini She has ownership interest in ROM Tech |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Kim Farina, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Andi Koral, MS, CMP-HC, Program Manager for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: October 22, 2025
EXPIRATION DATE: October 22, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited
